84211-30-3

Basic information

• Product Name: 3,4-Dihydroxy-5-Nitrobenzoic Acid
• Synonyms: 3,4-Dihydroxy-5-Nitrobenzoic Acid;Benzoic acid, 3,4-dihydroxy-5-nitro-
• CAS NO: 84211-30-3
• Molecular Formula: C₇H₅NO₆
• Molecular Weight: 199.12
• Mol File: 84211-30-3.mol

Chemical Properties

• Boiling Point: 411.1°C at 760 mmHg
• Flash Point: 188°C
• Appearance: /
• Density: 1.799g/cm³
• Vapor Pressure: 1.7E-07mmHg at 25°C
• Refractive Index: 1.715
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: 3,4-Dihydroxy-5-Nitrobenzoic Acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-Dihydroxy-5-Nitrobenzoic Acid(84211-30-3)
• EPA Substance Registry System: 3,4-Dihydroxy-5-Nitrobenzoic Acid(84211-30-3)

Safety Data

• Hazardous Substances Data: 84211-30-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3,4-Dihydroxy-5-Nitrobenzoic Acid is used as a synthetic intermediate for the production of Entacapone, a medication that acts as a peripherally selective inhibitor of catechol-O-methyltransferase (COMT). This enzyme inhibition helps in the management of Parkinson's disease by increasing the availability of dopamine in the brain, thus alleviating symptoms and improving motor function.
Additionally, 3,4-Dihydroxy-5-Nitrobenzoic Acid is utilized in the synthesis of antiparkinsonian drugs, which are designed to treat the motor symptoms associated with Parkinson's disease. Its role in the development of these medications highlights its importance in the pharmaceutical sector for the treatment and management of neurological disorders.

InChI:InChI=1/C7H5NO6/c9-5-2-3(7(11)12)1-4(6(5)10)8(13)14/h1-2,9-10H,(H,11,12)

Upstream product

• 116313-85-0 3,4-dihydroxy-5-nitrobenzaldehyde 
• 42590-00-1 4-hydroxy-3-methoxy-5-nitrobenzoic acid methyl ester 
• 3943-74-6 4-hydroxy-3-methoxybenzoic acid methyl ester 
• 15785-54-3 5-nitrovanillic acid 

Downstream Products

• 116314-97-7 3,4-diacetoxy-5-nitrobenzoic acid 
• 125629-01-8 methyl 3,4-dihydroxy-5-nitro-benzoate 
• 148546-85-4 methyl 3-amino-4,5-dimethoxybenzoate 
• 148546-84-3 methyl 3,4-dimethoxy-5-nitrobenzoate 
• 84211-27-8 3-amino-4,5-dihydroxybenzoic acid 
• 119734-29-1 (6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-1-carboxy-1-methyl-ethoxyimino]-acetylamino}-3-{[(3,4-dihydroxy-5-nitro-benzoyl)-ethyl-amino]-methyl}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 
• 119734-80-4 (6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-1-carboxy-1-methyl-ethoxyimino]-acetylamino}-3-[(3,4-dihydroxy-5-nitro-benzoylamino)-methyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 
• 119734-76-8 (6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-ethoxyimino]-acetylamino}-3-[(3,4-dihydroxy-5-nitro-benzoylamino)-methyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 
• 112057-05-3 3,4-diacetoxy-5-nitrobenzoyl chloride 

Relevant articles and documents

Synthesis of proposed structure of aaptoline a, a marine sponge-derived 7,8-dihydroxyquinoline, and its neuroprotective properties in c. Elegans

A concise and efficient synthesis of the proposed structure of aaptoline A, a 7,8-dihy-droxyquinoline derived from a marine sponge, was accomplished in seven steps with a 52% overall yield. A key feature of the synthesis is the high-yielding Ag(I)-catalyz

DUOCARMYCIN ANALOGUES

The invention relates to 2-methylbenzoxazole compounds of formula I which are analogues of the DNA alkylating subunit of the duocarmycins. Compounds of formula I can be used in the synthesis of DNA alkylating agents and antibody-drug conjugates and relate

Design and structural analysis of aromatic inhibitors of type II dehydroquinase from mycobacterium tuberculosis

3-Dehydroquinase, the third enzyme in the shikimate pathway, is a potential target for drugs against tuberculosis. Whilst a number of potent inhibitors of the Mycobacterium tuberculosis enzyme based on a 3-dehydroquinate core have been identified, they generally show little or no in vivo activity, and were synthetically complex to prepare. This report describes studies to develop tractable and drug-like aromatic analogues of the most potent inhibitors. A range of carbon-carbon linked biaryl analogues were prepared to investigate the effect of hydrogen bond acceptor and donor patterns on inhibition. These exhibited inhibitory activity in the high-micromolar range. The addition of flexible linkers in the compounds led to the identification of more potent 3-nitrobenzylgallate- and 5-aminoiso-phthalate-based analogues.

Small Molecule Xanthine Oxidase Inhibitors and Methods of Use

Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia.

Discovery of a long-acting, peripherally selective inhibitor of catechol- O -methyltransferase

Novel nitrocatechol-substituted heterocycles were designed and evaluated for their ability to inhibit catechol-O-methyltransferase (COMT). Replacement of the pyrazole core of the initial hit 4 with a 1,2,4-oxadiazole ring resulted in a series of compounds endowed with longer duration of COMT inhibition. Incorporation of a pyridine N-oxide residue at position 3 of the 1,2,4-oxadiazole ring led to analogue 37f, which was found to possess activity comparable to entacapone and lower toxicity in comparison to tolcapone. Lead structure 37f was systematically modified in order to improve selectivity and duration of COMT inhibition as well as to minimize toxicity. Oxadiazole 37d (2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4, 6-dimethylpyridine 1-oxide (BIA 9-1067)) was identified as a long-acting, purely peripheral inhibitor, which is currently under clinical evaluation as an adjunct to l-Dopa therapy of Parkinson's disease.

Oxadiazole derivatives as COMT inhibitors

This invention relates to novel substituted [1,2,4]-oxadiazoles, their use in the treatment of some central and peripheral nervous system disorders, methods for their preparation and pharmaceutical compositions containing them.

Improved method for demethylation of nitro-catechol methyl ethers

Several nitro-catechol compounds, useful as inhibitors of COMT were obtained in excellent yield and purity via an improved procedure for demethylation of the corresponding methyl ethers using aluminium chloride and pyridine in ethyl acetate.

Catechol derivatives

Catechol derivatives of the formula STR1 wherein Ra, Rb and Rc have the significance given herein, the ester and ether derivatives thereof which are hydrolyzable under physiological conditions and the pharmaceutically acceptable salts thereof are described and possess valuable pharmacological properties. In particular, they inhibit the enzyme catechol-O-methyltransferase (COMT), a soluble, magnesium-dependent enzyme which catalyses the transference of the methyl group of S-adensoylmethionine to a catechol substrate, whereby the corresponding methyl ethers are formed. Suitable substrates which can be O-methylated by COMT and which can thus be deactivated are, for example, extraneuornal catecholamines and exogeneously-administered therapeutically active substances having a catechol structure. Formula Ia above embraces not only compounds which form part of the invention, but also known compounds; the compounds which form part of the invention can be prepared according to known methods.